BrightSpring Health Services Reports Robust Q1 2026 Results and Raises Full-Year Guidance

Key Financial and Strategic Highlights for Investors

BrightSpring Health Services, Inc. (NASDAQ: BTSG), a leading provider of home and community-based health services for complex populations, has delivered a standout performance for the first quarter of 2026, posting significant growth across all key metrics and raising its full-year guidance. The company also completed a major divestiture and executed a sizable share repurchase—developments that could have a material impact on its share price.

Q1 2026 Financial Highlights

• Net revenue: \$3.61 billion, up 25.6% from \$2.88 billion in Q1 2025.
• Gross profit: \$482 million, up 42.5% from \$338 million in Q1 2025.
• Net income: \$74 million, a dramatic increase from \$9 million in Q1 2025.
• Adjusted EBITDA: \$190 million, up 44.8% from \$131 million in Q1 2025.
• Leverage ratio: Reduced to 2.27x as of March 31, 2026, from 2.60x (pro forma) at December 31, 2025.

Divestiture and Capital Management Actions

• Divestiture: The company closed the sale of its Community Living business to Sevita on March 30, 2026, resulting in a \$31.2 million after-tax gain (recorded in discontinued operations). This strategic move streamlines BrightSpring’s focus on core operations and improves its financial profile.
• Secondary Equity Offering and Share Repurchase: In March 2026, affiliates of Kohlberg Kravis Roberts & Co. L.P. (KKR) and certain management members conducted an underwritten secondary offering of the company’s common stock. Concurrently, BrightSpring repurchased \$60 million worth of shares (1,464,807 shares), enhancing value for remaining shareholders.

Segment Performance

• Pharmacy Solutions: Revenue rose 25% to \$3.17 billion. Segment EBITDA surged 46% to \$169 million. However, prescriptions dispensed decreased slightly by 1% (10.73 million vs. 10.88 million last year), but revenue per script jumped 27% to \$295.56, while gross profit per script soared 50% to \$28.03.
• Provider Services: Revenue increased 28% to \$442 million. Segment EBITDA climbed 29% to \$66 million. Key drivers included a 52% increase in average daily census in Home Health Care (46,066 vs. 30,241) and a 14% increase in Rehab Care persons served.

Raised Full-Year 2026 Guidance

• Revenue: Now expected to be in the range of \$14.73 billion to \$15.23 billion, representing 14.1% to 17.9% growth (excludes Community Living business).
• Pharmacy Segment Revenue: \$12.85–\$13.30 billion (12.3% to 16.2% growth).
• Provider Segment Revenue: \$1.88–\$1.93 billion (28.0% to 31.4% growth).
• Total Adjusted EBITDA: Upgraded to \$795–\$825 million (28.7% to 33.6% growth). The recently completed Amedysis and LHC acquisition is projected to contribute approximately \$30 million in Adjusted EBITDA in 2026.

Balance Sheet and Capital Position

• Cash and cash equivalents: \$889 million as of March 31, 2026 (up from \$88 million at December 31, 2025), reflecting strong cash generation and proceeds from the Community Living divestiture.
• Total assets: \$6.21 billion; Total equity: \$1.98 billion.
• Total liabilities: \$4.22 billion, including long-term debt of \$2.44 billion.

Cash Flow Highlights

• Net cash provided by operating activities: \$123 million (Q1 2026).
• Net cash from investing activities: \$747 million (mainly from the divestiture).
• Net cash used in financing activities: \$70 million (includes share repurchase and debt repayments).

Other Notable Items

• Adjusted EPS: \$0.39, up from \$0.19 in Q1 2025.
• Net income per diluted share: \$0.34 from continuing operations in Q1 2026, up from \$0.05 in Q1 2025.
• Supplemental information and webcast: The company is hosting a conference call and has posted additional materials for investors on its website.

Potential Price-Sensitive Developments for Shareholders

• Surge in Profitability: The significant increases in net income, gross profit, and Adjusted EBITDA, coupled with improved leverage, signal robust operational improvements. Such profitability growth is likely to be viewed positively by the market.
• Divestiture of Community Living Business: The closing of this transaction, gain realization, and the resulting cash inflow strengthen BrightSpring’s financial position and strategic focus.
• Share Repurchase: The buyback associated with the secondary offering demonstrates management’s confidence in the company’s intrinsic value and could be accretive to EPS.
• Raised Guidance: Upward revision of revenue and EBITDA forecasts for 2026, and contribution from new acquisitions (Amedysis and LHC), are material positive signals.
• Segmental Growth and Margin Expansion: Pharmacy revenue per script and gross profit per script have grown dramatically, indicating strong pricing power and operational efficiency.
• Risk Factors: Management highlighted several risks in their forward-looking statement, including regulatory changes, labor market pressures, reimbursement rate uncertainty, and integration risks. Investors should be aware that while the results are strong, future performance is subject to these risks.

Conclusion

BrightSpring Health Services has delivered a highly positive quarter, outperforming on both the top and bottom lines, executing strategic transactions to streamline its business, and boosting its outlook for the remainder of 2026. The combination of strong results, improved guidance, and strategic actions are all potentially price-sensitive and could positively influence the company’s share value.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. The content is based on currently available financial results and company disclosures, and actual future performance may differ due to various risks and uncertainties. Investors should conduct their own due diligence and consult with their financial advisors before making investment decisions.

View BrightSpring Health Services, Inc. Historical chart here